DongKook Life Science
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DongKook Life Science makes contrast agents, injectable medicines that make organs, blood vessels, and tissue show up clearly on medical scans such as X-ray, CT, and MRI, supplied exclusively to hospitals as prescription-only drugs.
Its products span iodine-based agents for X-ray and CT imaging, gadolinium-based agents for MRI, and iodised-oil agents used in interventional radiology procedures. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core business is contrast agents, which it complements with a separate division that imports, distributes, and manufactures diagnostic imaging equipment and medical devices. It supplies partners across roughly two dozen countries worldwide.
Summary is AI-generated and may contain errors · figures from DART filings
The company distributes its contrast agents through a network of partners spanning over two dozen countries, giving it an international commercial footprint unusual for a KOSDAQ-listed specialist pharmaceutical firm.
DongKook Life Science in five facts
What does DongKook Life Science do?
DongKook Life Science makes contrast agents, injectable medicines that make organs, blood vessels, and tissue show up clearly on medical scans such as X-ray, CT, and MRI, supplied exclusively to hospitals as prescription-only drugs.
Where is DongKook Life Science listed and in which sector?
DongKook Life Science (Korean name: 동국생명과학) trades under KRX code 303810 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is DongKook Life Science?
Its market capitalisation was US$60.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were DongKook Life Science's latest annual revenue and operating profit?
For fiscal year 2025, DongKook Life Science reported revenue of US$98.4M, operating profit of US$9.8M and net income of US$6.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 1.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.